Not financial advice. Content by Guerilla Finance Inc. is for educational and informational purposes only. Always conduct your own due diligence. Full disclaimer
FDA Guide

What is a PDUFA Date?
The FDA's Drug Approval Deadline, Explained

A PDUFA date is the single most important event in biotech investing. It's the FDA's self-imposed deadline to approve or reject a drug — and for small-cap biotech companies, it can mean a 200% gain or an 80% crash in a single day.

✍️ Richard Burke📅 April 2026⏱️ 10 min read

What PDUFA Stands For

PDUFA stands for the Prescription Drug User Fee Act, a U.S. law first passed in 1992. Under PDUFA, pharmaceutical and biotech companies pay user fees directly to the FDA when they submit drug applications. In exchange, the FDA commits to reviewing those applications within a fixed timeframe — and the deadline for that decision is called the PDUFA date (also called the PDUFA action date).

Before PDUFA, FDA drug reviews had no consistent timeline — some took a decade or more. The act transformed the FDA into a more predictable, deadline-driven agency, which is why investors can now track exact dates months in advance.

Key Takeaway

A PDUFA date is the FDA's deadline to make a final decision on a drug application. It is set before the review begins and is publicly knowable — making it a predictable, calendar-based catalyst that investors can prepare for in advance.

How the PDUFA Review Clock Works

When a company finishes clinical trials and wants to sell a drug in the U.S., it submits either a New Drug Application (NDA) for small-molecule drugs or a Biologics License Application (BLA) for biologics (antibodies, cell therapies, etc.). The process from there:

  1. Submission: Company files the NDA or BLA with the FDA.
  2. Filing decision (Day 60): FDA accepts or refuses to file. If accepted, the review clock starts.
  3. PDUFA date set: 10 months (standard) or 6 months (priority) from the Day 60 filing acceptance date.
  4. Review period: FDA advisory committees may meet; the company may receive information requests.
  5. PDUFA date: FDA issues its decision — approve, request more data, or extend the review.

Standard Review vs Priority Review

The FDA operates two main review tracks that determine how far out the PDUFA date is set:

Standard Review
10-month PDUFA date
For drugs that offer a modest benefit over existing therapies. The vast majority of drug applications.
Priority Review
6-month PDUFA date
For drugs that offer major advances in treatment or fill an unmet need for a serious condition.

Additional FDA designations that can accelerate review include Breakthrough Therapy, Fast Track, and Accelerated Approval — all of which signal that the FDA considers the drug particularly important and may engage more intensively during the review.

What Happens on PDUFA Day

The PDUFA date is not a specific time — the FDA can issue its decision at any point on that day, often early morning Eastern time. Investors and traders watch for the decision in real time via the FDA website, SEC filings (8-K press release), and news services.

In the days leading up to the PDUFA date, biotech stocks typically experience increased volatility as traders position for the binary event. Options implied volatility (IV) usually spikes sharply in the final 1-2 weeks. This is why understanding PDUFA dates is critical not just for long investors but for options traders as well.

Reading the Outcomes: Approval, CRL, Delay

There are three main outcomes on a PDUFA date:

✅ Approval
The FDA approves the drug for commercial sale. The company can begin marketing. This is the bull case — stocks typically gap up 20-200%+ depending on how widely expected the approval was and the drug's commercial potential.
❌ Complete Response Letter (CRL)
The FDA declines to approve the drug in its current form and requests additional data, studies, or manufacturing changes. This is not a final rejection — companies can resubmit — but it resets the timeline by 1-2+ years. Stocks typically drop 40-80% on a CRL.
⏳ PDUFA Date Extension / Delay
The FDA extends the review by 3 months to address outstanding questions, review late-cycle data, or handle manufacturing inspections. Less severe than a CRL — the drug may still be approved, just on a delayed timeline. Stock reaction is typically a moderate decline of 10-30%.

Why PDUFA Dates Matter to Investors

For small and mid-cap biotech companies, PDUFA dates represent one of the clearest binary catalysts in all of investing. A single FDA decision can:

  • Make a drug worth billions in annual revenue — or worthless
  • Double or halve the company's stock price in a single trading session
  • Trigger institutional buying, index inclusion, or secondary offerings
  • Determine whether the company survives (many single-asset biotechs have no revenue stream if their lead drug fails)

For large-cap pharma companies like Pfizer or AstraZeneca, individual PDUFA dates move the needle less — they have diversified pipelines. But for companies like a clinical-stage oncology or gene therapy firm where one drug is the company, the PDUFA date is existential.

Risk Warning

Trading around PDUFA dates carries extreme binary risk. Stocks can move 50-200% in either direction. Options strategies (spreads, straddles) can lose 100% of their value due to IV crush after the decision, even when the underlying stock moves in your favor. Always understand your full risk exposure. Nothing in this guide is investment advice.

How to Find Upcoming PDUFA Dates

There are several ways to track PDUFA dates:

  • FDA.gov — The official source. Under each drug's application page, the PDUFA date is published once the FDA accepts the filing. Updated but not always easy to navigate.
  • Company press releases & SEC 8-K filings — Companies almost always announce their PDUFA date in a press release when the FDA accepts their filing. Searchable on SEC EDGAR.
  • BiotechSigns PDUFA Calendar — Aggregates upcoming PDUFA dates across 8,000+ biotech companies into a browsable, filterable calendar. Updated daily by sentinel scrapers monitoring FDA, SEC, and clinical trial databases.
Track Every PDUFA Date

BiotechSigns tracks 125+ active PDUFA dates across 8,000+ biotech companies. Filter by your watchlist, sorted by days until decision.

Frequently Asked Questions

Q: What does PDUFA stand for?
PDUFA stands for the Prescription Drug User Fee Act, a U.S. law enacted in 1992 that created a system where pharmaceutical companies pay fees to the FDA in exchange for the agency committing to review drug applications within a fixed timeframe.
Q: Can a PDUFA date be moved?
Yes. The FDA can extend the PDUFA date by three months to request additional information, conduct manufacturing inspections, or complete an advisory committee review. Companies may also request a voluntary extension. The FDA cannot simply miss a PDUFA date without explanation.
Q: What is a Complete Response Letter (CRL)?
A CRL is the FDA's formal notification that a drug application cannot be approved in its current form. It is not a final rejection — it outlines what additional information or changes the FDA needs before it will reconsider. Companies typically resubmit within 1-3 years.
Q: How is a PDUFA date different from an AdCom meeting?
An advisory committee (AdCom) meeting is an external expert panel convened by the FDA to provide non-binding recommendations on a drug. It happens before the PDUFA date, typically 1-3 months prior. A favorable AdCom vote increases approval odds significantly but does not guarantee approval.
Q: Do all drug applications have a PDUFA date?
Most NDA and BLA applications for prescription drugs do. Over-the-counter drugs follow a different (OTC monograph) pathway and do not have traditional PDUFA dates. Generic drugs fall under the ANDA pathway with different PDUFA fee structures and timelines.
R
Richard Burke
Founder of Guerilla Finance Inc.. Builder of BiotechSigns, DilutionWatch, and StonkWhisper. Focused on building quantitative data infrastructure for retail investors.
About BiotechSigns →